Pharmacological cancer treatment and venous thromboembolism risk
Muñoz Martín, Andrés J. (Hospital General Universitario Gregorio Marañón)
Ramírez, Sara Pérez (Hospital General Universitario Gregorio Marañón)
Morán, Laura Ortega (Hospital General Universitario Gregorio Marañón)
Zamorano, Magdalena Ruiz (Universidad Complutense de Madrid)
Benéitez, María Carmen Viñuela (Universidad Complutense de Madrid)
Salcedo, Inmaculada Aparicio (Hospital General Universitario Gregorio Marañón)
Escobar, Ignacio García (Hospital General Universitario de Ciudad Real)
Soria Fernández, José Manuel (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Arterial thromboembolism ; Cancer ; Chemotherapy ; Hormonotherapy ; Immunotherapy ; Supportive care ; Targeted therapy ; Venous thromboembolism
Published in:	European heart journal supplements, Vol. 22 (2020) , p. C2-C14, ISSN 1554-2815

DOI: 10.1093/EURHEARTJ/SUAA004
PMID: 32368194

13 p, 423.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles